News | December 30, 2022
Cipla EU to invest € 15 million in Ethris
Cipla and Ethris partner for the development of mRNA-based therapies
Cipla and Ethris partner for the development of mRNA-based therapies
The new facility will be able to handle four times as many patients as the previous facility.
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The organisation is also working towards providing skills based training programmes to the workers for paramedical jobs and has launched certificate courses in ten disciplines
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
The expansion in Indore is well-aligned with Lupin Diagnostics’ commitment to improving access to high-quality, reliable, and advanced testing centres and home collection facilities at an affordable price
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
He has published more than 100 research papers in several prestigious national and international journals
Subscribe To Our Newsletter & Stay Updated
